Glooko acquires fellow diabetes management company DIABNEXT and more digital health briefs

Digital diabetes management company Glooko has acquired Paris-basedDIABNEXT, a fellow diabetes care platform.

DIABNEXT’s app tracks affected person diabetes metrics, permitting suppliers to watch that knowledge and present care remotely. Glooko mentioned it’ll supply its personal platform and DIABNEXT, rebranded as Glooko XT, for the French market.

“We are very pleased to welcome the DIABNEXT team to Glooko and especially excited to add their well-regarded product to Glooko’s portfolio, along with their expertise in the diabetes community in France,” Glooko CEO Russ Johannesson mentioned in an announcement.

“The addition of DIABNEXT expands our offerings with a unique platform that can help us better customize the patient experience and improve health outcomes for people with diabetes. Glooko’s acquisition of DIABNEXT further cements our commitment to increase our global presence and continue to drive innovative solutions. “

This is Glooko’s second acquisition this 12 months. In January, the company introduced it had bought Berlin-based xbird, maker of AI-based diabetes care instruments. The company raised $30 million in Series D funding final 12 months.

Dadwhich affords in-home help for seniors or different susceptible populations, introduced Wednesday it is increasing into the employer market.

The startup mentioned partnerships with employers will present caregiving assist for employees who need to assist elderly, chronically ill or disabled family members along with their paid work.

“For employees, the impossible balancing act between one’s work and family roles impacts them, their dependents, and ultimately their employer,” Andrew Parker, founder and CEO of Papa, mentioned in an announcement.

“Papa has shown success with Medicare Advantage and Medicaid members in terms of reduced loneliness and improved health, and we believe there is tremendous opportunity to extend our model to flexible family care, for help when, where, and how it’s most needed.”

In late 2021, Dad scooped up $150 million in Series D funding.

Digital chronic-condition management companyLark Health is creating an AI-enabled platform for stopping and managingatherosclerotic heart problems (ASCVD) and coronary artery illness (CAD) in partnership with Roche Diagnostics.

The Lark Heart Health program, which is ready to launch later this 12 months, makes use of the ideas of cognitive behavioral remedy to supply teaching round wholesome behaviors and lowering stress.

“Lark Heart Health will help those at high risk prevent and actively manage cardiovascular disease through personalized digital coaching,” cofounder and CEO Julia Hu mentioned in an announcement. “By leveraging our AI technology, we can deliver meaningful and engaging care at an unprecedented scale, and this collaboration with Roche Diagnostics will support the expansion of our proven tech platform into one of the costliest chronic disease markets.”


Leave a Reply

Your email address will not be published. Required fields are marked *

Check Also
Back to top button